Verition Fund Management LLC Makes New $415,000 Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Verition Fund Management LLC acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,472 shares of the medical instruments supplier’s stock, valued at approximately $415,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LMAT. Price T Rowe Associates Inc. MD raised its holdings in LeMaitre Vascular by 14.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,643 shares of the medical instruments supplier’s stock worth $375,000 after purchasing an additional 695 shares in the last quarter. SG Americas Securities LLC acquired a new stake in LeMaitre Vascular during the second quarter worth approximately $177,000. Hennion & Walsh Asset Management Inc. raised its holdings in LeMaitre Vascular by 62.2% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 10,289 shares of the medical instruments supplier’s stock worth $847,000 after purchasing an additional 3,947 shares in the last quarter. Fifth Third Bancorp raised its holdings in LeMaitre Vascular by 6.6% during the second quarter. Fifth Third Bancorp now owns 10,888 shares of the medical instruments supplier’s stock worth $896,000 after purchasing an additional 678 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in LeMaitre Vascular by 3.1% during the second quarter. Louisiana State Employees Retirement System now owns 10,100 shares of the medical instruments supplier’s stock worth $831,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LMAT has been the topic of a number of research reports. Oppenheimer restated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. JMP Securities raised their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $100.28 on Friday. The firm’s fifty day moving average price is $97.47 and its 200 day moving average price is $89.33. LeMaitre Vascular, Inc. has a 1-year low of $52.79 and a 1-year high of $109.58. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of 54.80, a price-to-earnings-growth ratio of 2.48 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business’s revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 EPS. As a group, analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.64%. LeMaitre Vascular’s payout ratio is currently 34.97%.

Insiders Place Their Bets

In other news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.